The global exosome diagnostic and therapeutic market is poised for substantial growth, with market size projected to expand from USD 88.56 million in 2024 to USD 211.6 million by 2034, achieving an impressive CAGR of 9.1% over the forecast period. This growth is driven by the increasing demand for non-invasive biomarkers and advancements in precision medicine.
Key Growth Drivers: Non-Invasive Biomarkers and Personalized Medicine
Exosomes, which are small extracellular vesicles, are gaining traction as non-invasive biomarkers due to their role in intercellular communication and their potential in early disease detection, monitoring, and therapeutic delivery. Their utility in precision medicine and targeted therapies further enhances their appeal, making them a key focus in oncology, neurology, and other medical fields.
Market Opportunities: Advancements in Research and Technology
Ongoing advancements in exosome isolation and characterization technologies are expected to unlock new opportunities in the diagnostic and therapeutic domains. Investment in research and development is paving the way for innovative applications, including drug delivery systems and liquid biopsies.
Full Report Revealed – https://www.futuremarketinsights.com/reports/exosome-diagnostic-and-therapeutics-market
Key Takeaways
- The exosome diagnostic and therapeutic market is projected to grow at a CAGR of 9.1% from 2024 to 2034.
- Market valuation will increase from USD 88.56 million in 2024 to USD 211.6 million by 2034.
- Rising demand for non-invasive biomarkers drives growth, particularly in oncology and neurology.
- Advancements in exosome-related technologies enhance their utility in diagnostics and drug delivery.
- Research and development efforts are expected to uncover novel applications and expand the market further.
The exosome diagnostic and therapeutic market’s rapid growth underscores its potential to revolutionize healthcare by enabling early diagnosis, personalized treatments, and effective therapeutic delivery systems. Industry stakeholders are well-positioned to leverage these advancements to improve patient outcomes globally.
Growth Drivers
- Increasing Demand for Non-Invasive Biomarkers: The rising preference for non-invasive diagnostic methods is driving the demand for exosome-based diagnostics, as they offer a less invasive alternative for monitoring various health conditions, particularly in cancer research.
- Advancements in Exosome Technology: Continuous innovations in exosome isolation and analysis technologies are enhancing their application in diagnostics and therapeutics, making them more effective and reliable.
- Growing Incidence of Chronic Diseases: The increasing prevalence of chronic diseases, particularly cancer, is creating a higher demand for effective diagnostic tools that can facilitate early detection and personalized treatment strategies.
- Rising Research and Development Investments: Increased funding and investment in research related to exosomes are accelerating the development of new diagnostic and therapeutic applications, further propelling market growth.
- Regulatory Support and Collaboration: Supportive regulatory frameworks and collaborations between research institutions and healthcare organizations are fostering advancements in exosome diagnostics and therapeutics.
Market Trends
- The market is witnessing a shift towards utilizing exosomes as biomarkers for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.
- There is a growing focus on the therapeutic potential of exosomes, including their use in drug delivery systems and regenerative medicine.
Regional Insights
- North America is expected to dominate the market due to advanced healthcare infrastructure, high prevalence of chronic diseases, and strong research capabilities.
- The Asia-Pacific region is projected to experience significant growth driven by increasing healthcare investments and rising awareness of advanced diagnostic technologies.
Competitive Landscape
The exosome diagnostic and therapeutic industry is experiencing a high level of competition, thanks to the growing count of companies manufacturing exosome-based products. All known companies in the market are covered below. Along with the companies, the technology that they are working on is also described. The following companies may or may not be working with any regulatory agencies, however, many of them do.
AcouSort AB
It is a Swedish firm that is introducing a revolutionary acoustofluidic technology and working on exosome-based diagnostics. The European Innovation Council (EIC) rewarded AcouSort and its project partners with a total of US$ 2.5 million to create acoustofluidic thin-film actuated chip to separate exosomes from blood.
Aethlon Medical, Inc.
It is a United States-based company that focuses on addressing the unmet requirements in the global health and biodefense industry. The firm began its tumor-derived exosome research when the medical community held a view that exosomes are cellular debris.
Fast-forward to the present, a therapeutic to attend to tumor-derived exosomes presents a significant gap in cancer care. Aethlon has shown that Hemopurifier®’s affinity mechanism can detect tumor-derived exosomes behind various forms of cancer, like ovarian, breast, and metastatic melanoma.
AGC Biologics
AGC Biologics came into a service agreement with Japan’s Jikei University in April 2023. This agreement states that AGC Biologics is going to assume a feasibility study and technology transfer for a drug to cure idiopathic pulmonary fibrosis (IPF). Specifically, the ACG scientists are going to focus on recognizing the viability of developing a sample for an exosome-based treatment.
Aruna Bio
The company is leveraging the natural abilities of neural exosomes to pass the blood-brain barrier and elevate the body’s anti-inflammatory, protective, and self-repair mechanisms for neurodegenerative disorders treatment.
Latest Developments in the Exosomes Diagnostic and Therapeutic Market
- Thermo Fisher Scientific introduced the Thermo Scientific KingFisher Apex Purification System in April 2021. This system is a high-throughput sample purification tool that is developed for scientists who want to automate the extraction of RNA, DNA, cells, and protein from an array of sample types. The system helps enhance research productivity and propel discoveries by automating and simplifying the sample preparation workflow.
- In February 2022, Bio-Techne Corporation made public its agreement with Thermo Fisher Scientific. Under this agreement, the latter company will be helping a Bio-Techne brand called Exosome Diagnostics to develop and commercialize the ExoTRU kidney transplant rejection test.
Key Players in the Exosomes Diagnostic and Therapeutic Market
- Thermo Fisher Scientific
- NanoSomix
- NX Pharmagen
- Malvern Instruments
- Capricor Therapeutic
- Exosome Diagnostics
- Exiqon A/S
- System Biosciences
- Exosome Sciences
- Aegle Therapeutic
- AMS Biotechnology
- Miltenyi Biotec
- Codiak BioSciences Inc.
- Lonza Group (HansaBioMed Life Sciences Ltd.)
- AcouSort AB
- Aethlon Medical, Inc.
- AGC Biologics
- Anjarium Biosciences AG
- Aruna Bio
- Brexogen
- Capricor Therapeutics
- Cells for Cells
- Ciloa
- ConvEyXO
- Others
Exosomes Diagnostic and Therapeutic Market Research by Categories
By Products for Exosomes Diagnostic and Therapeutic are as follows:
- Instruments
- Software
- Reagents and Kits
The Market is Bifurcated Based on Applications as:
- Diagnostics
- Therapeutic
Key End Users of Exosomes Diagnostic and Therapeutic are:
- Hospitals
- Cancer Institutes
- Diagnostic Centers
- Others
Different Markets for Exosomes Diagnostic and Therapeutic are:
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
